Moreover, the principal mechanisms of CXD101 anti-tumour activity may be independent of HR23B and inhibition of proteasome function, for example through changes in histone structure or changes to acetylation states of non-histone proteins such as the tumour suppressor p53 [26–28]. Here, RAD23B is linked to neoplasm.